Literature DB >> 11882331

Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty.

Yukihiro Hojo1, Uichi Ikeda, Taka aki Katsuki, Osamu Mizuno, Hideyuki Fujikawa, Kazuyuki Shimada.   

Abstract

Recent studies have revealed that matrix metalloproteinases (MMPs) play an important role in cardiovascular remodeling by degrading the extracellular matrix. We investigated changes in the expression of MMPs due to percutaneous transluminal coronary angioplasty (PTCA). We studied 47 patients with ischemic heart disease who underwent elective PTCA on isolated stenotic lesion of left coronary arteries. Twelve patients received conventional balloon angioplasty, 14 percutaneous transluminal rotational atherectomy and 21 stent implantation. Blood samples were drawn from the coronary sinus immediately before and after, as well as 4 and 24 h, after PTCA. Plasma levels of MMP-1, MMP-2, tissue inhibitor of MMP (TIMP)-1 and TIMP-2 were measured by enzyme-linked immunosorbent assay. Plasma MMP-2 activity was determined with the digestion of a specific chromogenic peptide substrate. We could observe serial changes in plasma MMP-1 levels in the coronary circulation only in one patient, because MMP-1 levels were lower than the limit of detection in other patients. On the other hand, plasma MMP-2 levels in the coronary sinus were detectable in all subjects and increased significantly 4 and 24 h after PTCA. Plasma TIMP-1 levels also showed significant increases 4 and 24 h after PTCA, whereas TIMP-2 did not show significant changes. Plasma MMP-2/TIMP-2 ratio and MMP-2 activity in the coronary sinus showed significant increases 4 and 24 h after PTCA. A positive correlation was observed between MMP-2 levels in the coronary sinus 4 h after PTCA and late loss index 6 months after PTCA. MMP-2 levels in the coronary sinus blood were significantly higher in patients with late restenosis than in those without restenosis. PTCA induces increases in plasma MMP-2 levels and activity in the coronary circulation, which may contribute to vascular remodeling and late restenosis after PTCA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882331     DOI: 10.1016/s0021-9150(01)00615-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

Review 2.  Restenosis after PCI. Part 1: pathophysiology and risk factors.

Authors:  J Wouter Jukema; Jeffrey J W Verschuren; Tarek A N Ahmed; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2011-09-13       Impact factor: 32.419

3.  Matrix metalloprotein-9 activation under cell-to-cell interaction between endothelial cells and monocytes: possible role of hypoxia and tumor necrosis factor-α.

Authors:  Yuko Yamamoto; Tomohiro Osanai; Fumie Nishizaki; Takanori Sukekawa; Kei Izumiyama; Shigeki Sagara; Ken Okumura
Journal:  Heart Vessels       Date:  2012-01-11       Impact factor: 2.037

Review 4.  Matrix metalloproteinases and peripheral arterial disease.

Authors:  Chiara Busti; Emanuela Falcinelli; Stefania Momi; Paolo Gresele
Journal:  Intern Emerg Med       Date:  2009-07-21       Impact factor: 3.397

Review 5.  Matrix metalloproteinases and atherosclerosis.

Authors:  Noboru Watanabe; Uichi Ikeda
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

6.  Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo.

Authors:  Stefania Momi; Emanuela Falcinelli; Silvia Giannini; Loredana Ruggeri; Luca Cecchetti; Teresa Corazzi; Claude Libert; Paolo Gresele
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.